Breast cancer and gender-affirming hormone therapy for transgender and gender-diverse (TGD) individuals.

Cathcart-Rake, Elizabeth J; Ruddy, Kathryn J; Tevaarwerk, Amye J; Jatoi, Aminah

Cathcart-Rake, Elizabeth J; Ruddy, Kathryn J; Tevaarwerk, Amye J; Jatoi, Aminah.

Afiliação

Cathcart-Rake EJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: Cathcart-rake.elizabeth@mayo.edu.
Ruddy KJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States of America.
Tevaarwerk AJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States of America.
Jatoi A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States of America.

Maturitas ; 181: 107913, 2024 Mar.

Article em En | MEDLINE | ID: mdl-38262089

ABSTRACT

ABSTRACT

Transgender and gender-diverse (TGD) individuals are at risk for breast cancer, but are less likely to undergo screening mammograms and appear to suffer poorer cancer-related outcomes than cisgender women. Gender-affirming hormone therapy (GAHT) may be lifesaving for TGD individuals from the perspective of affirming their core identities; however, the effects of GAHT on cancer development, progression, and outcomes are poorly understood.

Assuntos

Neoplasias da Mama; Pessoas Transgênero; Feminino; Humanos; Mamografia; Hormônios

Palavras-chave

Breast oncology; Gender diverse; Transgender

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Pessoas Transgênero Aspecto: Determinantes_sociais_saude Limite: Female / Humans Idioma: En Revista: Maturitas Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google